Table 1 Clinical characteristics of patients and their distrubution across PPI groups
Characteristic | PALBOCICLIB | RIBOCICLIB | ||||||
|---|---|---|---|---|---|---|---|---|
Total number of patients (n = 105) | Concomitant use of PPIs | P score | Total number of patients (n = 112) | Concomitant use of PPIs | P score | |||
No | Yes | No | Yes | |||||
Age, median (Range) | 59 (32–83) | 58 (35–76) | 61 (32–83) | - | 53 (32–87) | 49 (32–87) | 57 (38–87) | - |
Menopausal status, n(%) | ||||||||
Premenopause | 32(30.4) | 14(35.0) | 18(27.7) | 0.514 | 43(38.3) | 22(43.1) | 21(34.4) | 0.436 |
Postmenopause | 73(69.5) | 26(65.0) | 47(72.3) | 69(61.6) | 29(56.9) | 40(65.6) | ||
ECOG PS, n (%) | ||||||||
0 | 19(18) | 8(20.0) | 11(16.9) | 0.079 | 38(33.9) | 23(45.1) | 15(24.6) | 0.072 |
1 | 74(70.4) | 31(77.5) | 43(66.2) | 60(53.5) | 23(45.1) | 37(60.7) | ||
2 | 12(11.4) | 1(2.5) | 11(16.9) | 14((12.5) | 5(9.8) | 9(14.8) | ||
Disease site, n (%) | ||||||||
Visceral | 63(60) | 22(55.0) | 41(63.1) | 0.421 | 54(48.2) | 24(47.1) | 30(49.2) | 0.851 |
Nonvisceral | 42(40) | 18(45.0) | 24(36.9) | 58(51.7) | 27(52.9) | 31(50.8) | ||
Number of metastatic site, n (%) | ||||||||
< 3 | 95(91.5) | 37(92.5) | 58(89.2) | 0.738 | 98(87.5) | 47(92.2) | 51(83.6) | 0.252 |
≥ 3 | 10(9.5) | 3(7.5) | 7(10.8) | 14(12.5) | 4(7.8) | 10(16.4) | ||
Endocrine therapy, n (%) | ||||||||
Letrozolea | 49(46.6) | 23(57.5) | 26(40.0) | 0.107 | 66(58.9) | 34(66.7) | 32(52.5) | 0.177 |
Fulvestranta | 56(53.3) | 17(42.5) | 39(60.0) | 46(41) | 17(33.3) | 29(47.5) | ||
Dose Reduction, n (%) | ||||||||
Yes | 56(53.3) | 19(47.5) | 37(56.9) | 0.224 | 61(54.4) | 25(49.0) | 36(59.0) | 0.254 |
No | 49(46.7) | 21(52.5) | 28(43.1) | 51(45.6) | 26(51.0) | 25(41.0) | ||
CDK inhibitor intervalb | ||||||||
< 18 months | 65(61.9) | 27(67.5) | 38(58.5) | 0.411 | 86(76.7) | 41(80.4) | 45(73.8) | 0.502 |
≥ 18 months | 40(38) | 13(32.5) | 27(41.5) | 26(23.2) | 10(19.6) | 16(26.2) | ||
PPI, n (%) | ||||||||
Pantoprazole | 28(43.1) | 18(29.5) | ||||||
Rabeprazole | 17(26.2) | 10(16.4) | ||||||
Esomeprazole | 8(12.3) | 18(29.5) | ||||||
Lansoprazole | 9(13.8) | 3(4.9) | ||||||
Omeprazole | 3(4.6) | 12(19.7) | ||||||